{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Grade+II+Glioma&page=2", "query": { "condition": "Grade II Glioma", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Grade+II+Glioma&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-06-27T06:26:22.272Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00020579", "title": "MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "entinostat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institutes of Health Clinical Center (CC)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 75, "start_date": "2001-03", "completion_date": "2008-10", "has_results": false, "last_update_posted_date": "2012-03-15", "last_synced_at": "2026-06-27T06:26:22.272Z", "location_count": 3, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00020579" }, { "nct_id": "NCT00946335", "title": "ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Childhood Atypical Teratoid/Rhabdoid Tumor", "Childhood Central Nervous System Germ Cell Tumor", "Childhood Choroid Plexus Tumor", "Childhood Craniopharyngioma", "Childhood Ependymoblastoma", "Childhood Grade I Meningioma", "Childhood Grade II Meningioma", "Childhood Grade III Meningioma", "Childhood High-grade Cerebellar Astrocytoma", "Childhood High-grade Cerebral Astrocytoma", "Childhood Infratentorial Ependymoma", "Childhood Low-grade Cerebellar Astrocytoma", "Childhood Low-grade Cerebral Astrocytoma", "Childhood Medulloepithelioma", "Childhood Mixed Glioma", "Childhood Oligodendroglioma", "Childhood Supratentorial Ependymoma", "Recurrent Childhood Brain Stem Glioma", "Recurrent Childhood Brain Tumor", "Recurrent Childhood Cerebellar Astrocytoma", "Recurrent Childhood Cerebral Astrocytoma", "Recurrent Childhood Ependymoma", "Recurrent Childhood Medulloblastoma", "Recurrent Childhood Pineoblastoma", "Recurrent Childhood Spinal Cord Neoplasm", "Recurrent Childhood Subependymal Giant Cell Astrocytoma", "Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor", "Recurrent Childhood Visual Pathway and Hypothalamic Glioma" ], "interventions": [ { "name": "veliparib", "type": "DRUG" }, { "name": "temozolomide", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 31, "start_date": "2009-07", "completion_date": "2014-06", "has_results": false, "last_update_posted_date": "2014-07-09", "last_synced_at": "2026-06-27T06:26:22.272Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00946335" }, { "nct_id": "NCT00165360", "title": "Prolonged Daily Temozolomide for Low-Grade Glioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioma", "Astrocytoma", "Oligodendroglioma" ], "interventions": [ { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2001-09", "completion_date": "2009-09", "has_results": false, "last_update_posted_date": "2009-11-02", "last_synced_at": "2026-06-27T06:26:22.272Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00165360" }, { "nct_id": "NCT00538850", "title": "Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "Fentanyl sublingual spray", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "INSYS Therapeutics Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 130, "start_date": "2007-10", "completion_date": "2010-10", "has_results": true, "last_update_posted_date": "2014-03-05", "last_synced_at": "2026-06-27T06:26:22.272Z", "location_count": 1, "location_summary": "Chandler, Arizona", "locations": [ { "city": "Chandler", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00538850" }, { "nct_id": "NCT03434262", "title": "SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Anaplastic Astrocytoma", "Anaplastic Ependymoma", "Anaplastic Ganglioglioma", "Anaplastic Meningioma", "Anaplastic Oligodendroglioma", "Pleomorphic Xanthoastrocytoma, Anaplastic", "Atypical Teratoid/Rhabdoid Tumor", "Brain Cancer", "Brain Tumor", "Central Nervous System Neoplasms", "Choroid Plexus Carcinoma", "CNS Embryonal Tumor With Rhabdoid Features", "Ganglioneuroblastoma of Central Nervous System", "CNS Tumor", "Embryonal Tumor of CNS", "Ependymoma", "Glioblastoma", "Glioma", "Glioma, Malignant", "Medulloblastoma", "Medulloblastoma; Unspecified Site", "Medulloepithelioma", "Neuroepithelial Tumor", "Neoplasms", "Neoplasms, Neuroepithelial", "Papillary Tumor of the Pineal Region (High-grade Only)", "Pediatric Brain Tumor", "Pineal Parenchymal Tumor of Intermediate Differentiation (High-grade Only)", "Pineoblastoma", "Primitive Neuroectodermal Tumor", "Recurrent Medulloblastoma", "Refractory Brain Tumor", "Neuroblastoma. CNS", "Glioblastoma, IDH-mutant", "Glioblastoma, IDH-wildtype", "Medulloblastoma, Group 3", "Medulloblastoma, Group 4", "Glioma, High Grade", "Neuroepithelial Tumor, High Grade", "Medulloblastoma, SHH-activated and TP53 Mutant", "Medulloblastoma, SHH-activated and TP53 Wildtype", "Medulloblastoma, Chromosome 9q Loss", "Medulloblastoma, Non-WNT Non-SHH, NOS", "Medulloblastoma, Non-WNT/Non-SHH", "Medulloblastoma, PTCH1 Mutation", "Medulloblastoma, WNT-activated", "Ependymoma, Recurrent", "Glioma, Recurrent High Grade", "Glioma, Recurrent Malignant", "Embryonal Tumor, NOS", "Glioma, Diffuse Midline, H3K27M-mutant", "Embryonal Tumor With Multilayered Rosettes (ETMR)", "Ependymoma, NOS, WHO Grade III", "Ependymoma, NOS, WHO Grade II", "Medulloblastoma, G3/G4", "Ependymoma, RELA Fusion Positive" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "ribociclib", "type": "DRUG" }, { "name": "sonidegib", "type": "DRUG" }, { "name": "trametinib", "type": "DRUG" }, { "name": "filgrastim", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "39 Years", "sex": "ALL", "summary": "1 Year to 39 Years" }, "enrollment_count": 68, "start_date": "2018-03-05", "completion_date": "2024-05-24", "has_results": false, "last_update_posted_date": "2024-05-31", "last_synced_at": "2026-06-27T06:26:22.272Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03434262" }, { "nct_id": "NCT01204684", "title": "Dendritic Cell Vaccine for Patients With Brain Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioma", "Anaplastic Astrocytoma", "Anaplastic Astro-oligodendroglioma", "Glioblastoma" ], "interventions": [ { "name": "autologous tumor lysate-pulsed DC vaccination", "type": "BIOLOGICAL" }, { "name": "Tumor lysate-pulsed DC vaccination+0.2% resiquimod", "type": "BIOLOGICAL" }, { "name": "Tumor-lysate pulsed DC vaccination +adjuvant polyICLC", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 24, "start_date": "2010-10-08", "completion_date": "2024-08-21", "has_results": false, "last_update_posted_date": "2024-08-28", "last_synced_at": "2026-06-27T06:26:22.272Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01204684" }, { "nct_id": "NCT00003567", "title": "Gene Therapy and Chemotherapy in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain and Central Nervous System Tumors", "Lymphoma", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "therapeutic autologous lymphocytes", "type": "BIOLOGICAL" }, { "name": "O6-benzylguanine", "type": "DRUG" }, { "name": "carmustine", "type": "DRUG" }, { "name": "temozolomide", "type": "DRUG" }, { "name": "in vitro-treated peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 8, "start_date": "1999-05", "completion_date": "2007-02", "has_results": false, "last_update_posted_date": "2010-06-11", "last_synced_at": "2026-06-27T06:26:22.272Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003567" }, { "nct_id": "NCT00381797", "title": "Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Childhood Cerebral Anaplastic Astrocytoma", "Childhood Oligodendroglioma", "Childhood Spinal Cord Neoplasm", "Recurrent Childhood Brain Stem Glioma", "Recurrent Childhood Ependymoma", "Recurrent Childhood Medulloblastoma" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Fludeoxyglucose F-18", "type": "RADIATION" }, { "name": "Irinotecan Hydrochloride", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "RADIATION", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 97, "start_date": "2006-08", "completion_date": "2015-10", "has_results": true, "last_update_posted_date": "2017-11-28", "last_synced_at": "2026-06-27T06:26:22.272Z", "location_count": 11, "location_summary": "San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 7 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00381797" }, { "nct_id": "NCT05303519", "title": "SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Glioma", "Astrocytoma, Grade IV", "IDH1-mutant Glioma", "Astrocytoma, IDH-Mutant, Grade 3", "Astrocytoma, IDH-Mutant, Grade 4", "Astrocytoma, IDH-Mutant, Grade 2", "Oligodendroglioma", "Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted" ], "interventions": [ { "name": "safusidenib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nuvation Bio Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 365, "start_date": "2023-06-05", "completion_date": "2030-12-01", "has_results": false, "last_update_posted_date": "2026-06-11", "last_synced_at": "2026-06-27T06:26:22.272Z", "location_count": 40, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 32 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05303519" }, { "nct_id": "NCT01977677", "title": "Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Adult Ependymoblastoma", "Adult Giant Cell Glioblastoma", "Adult Glioblastoma", "Adult Gliosarcoma", "Adult Medulloblastoma", "Adult Mixed Glioma", "Adult Oligodendroglial Tumors", "Adult Pineoblastoma", "Adult Supratentorial Primitive Neuroectodermal Tumor (PNET)" ], "interventions": [ { "name": "radiation therapy", "type": "RADIATION" }, { "name": "temozolomide", "type": "DRUG" }, { "name": "plerixafor", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "RADIATION", "DRUG", "OTHER" ], "sponsor": "Lawrence Recht", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 30, "start_date": "2014-11", "completion_date": "2018-09", "has_results": true, "last_update_posted_date": "2018-10-23", "last_synced_at": "2026-06-27T06:26:22.272Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01977677" } ] }